Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation

PEDS024, Phase I/II Feasibility Study of Busulfan Fludarabine and Thiotepa Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) for Children With Non-Malignant Disorders

In this study, the investigators test 2 dose levels of thiotepa (5 mg/kg and 10 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG) to determine the minimum effective dose required for reliable engraftment for subjects undergoing hematopoietic stem cell transplantation for non-malignant disease.

Study Overview

• Status: Completed
• Conditions: Common Variable Immunodeficiency; Severe Combined Immunodeficiency; Sickle Cell Disease; Hurler Syndrome; Chronic Granulomatous Disease; Thalassemia; Wiskott-Aldrich Syndrome; Adrenoleukodystrophy; X-linked Lymphoproliferative Disease; Diamond Blackfan Anemia; Bone Marrow Failure Syndrome; Hemophagocytic Lymphohistiocytoses; Mannosidosis; Acquired Neutropenia in Newborn; Acquired Anemia Hemolytic; Acquired Thrombocytopenia
• Intervention / Treatment: Drug: Thiotepa--single daily dose; Drug: Thiotepa--escalated dose

Detailed Description

Hematopoietic stem cell transplantation is the only curative choice for a number of inherited bone marrow failure syndromes, hemoglobinopathies, metabolic disorders and primary immune deficiencies. While survival of these patients is typically better than survival of patients with malignancies, toxicities of conditioning regimens and failure of engraftment remain challenges. Most children with non-malignant disorders present with normocellular or even hypercellular bone marrow, posing a barrier to engraftment and requiring intensive conditioning. Commonly used backbone of busulfan and fludarabine, although well tolerated, results in variable engraftment, in particular with mismatched unrelated donors and cord blood recipients. In this study, the investigators test 2 dose levels of thiotepa (5 mg/kg and 10 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG) in order to determine the minimum effective dose required for reliable engraftment. Subjects are stratified in groups A and B based the risk of graft failure.

• Study Type: Interventional
• Enrollment (Actual): 6
• Phase: Phase 2; Phase 1

Contacts and Locations

Study Locations

• United States
  • Florida
    • Gainesville, Florida, United States, 32608
      • UF Health Shands Children's Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 1 year to 37 years (Child, Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Diagnoses:

  • Hemoglobinopathies (e.g. thalassemia or sickle cell disease),
  • Cytopenias (e.g.Diamond-Blackfan anemia, congenital or acquired neutropenia, congenital or acquired thrombocytopenia, congenital or acquired anemia, and others, regardless clonality),
  • Hemophagocytic lymphohistiocytosis,
  • Primary immunodeficiencies (e.g. Wiscott Aldrich Syndrome, chronic granulomatous disease, common variable immune deficiency, X-linked lymphoproliferative disease, NK+ severe combined immune deficiencies),
  • Metabolic disorders (Hurler's syndrome, mannosidosis, adrenal leuko-dystrophy)
  • Other non-malignant disorders for which there is published evidence that HSCT (hematopoietic stem cell transplant) is a curative therapy.

• Donor Requirements

  • Related or unrelated donor who is suitable and willing to donate bone marrow or peripheral blood stem cells. HLA typing should be done by high-resolution typing at A, B, C, DrB1 and DQ loci and the donor should be at a minimum ≥8/10 match (with one antigen/allele mismatch allowed at A, B, or C-loci and other at DQ loci).
  • Cord blood units must be matched at a minimum of 6/8 antigens/alleles at A, B, C and DrB1 loci. High resolution typing at all loci is required. The minimum TNC dose pre-cryopreservation must be ≥3.7 x10^7/kg of recipient's weight, if a single cord blood unit is used, or at least 2x10^7/kg per unit, if two cord blood units are used. The mismatches cannot be at the same loci (e.g. double A mismatch).
  • Haploidentical related stem cell donor who is suitable and willing to donate peripheral blood stem cells. T-cell depletion is required if haploidentical donors are used. Pharmacologic GVHD prophylaxis will not be used for T-cell depleted transplant recipients.

• Adequate organ function defined as:

  • Cardiac: ejection fraction ≥55% or shortening fraction ≥30%
  • creatinine clearance ≥70 ml/min/1.73m2
  • Pulse oximetry >95% on room air or FEV1/DLCO >60%
  • LFTs < 3 x ULN, Total bilirubin <3 mg/dl (unless due to non-hepatic cause (e.g. Gilbert's syndrome or hemolysis)
• Lansky/Karnofsky score ≥60%
• Written informed consent obtained from the subject or parental/guardian permission ± child's assent per institutional guidelines

• Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy for at least 1 month after completion of conditioning. WOCBP include any woman who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or who is not post-menopausal. Post-menopause is defined as:

  • Amenorrhea that has lasted for ≥ 12 consecutive months without another cause, or
  • For women with irregular menstrual periods who are taking hormone replacement therapy (HRT), a documented serum follicle-stimulating hormone (FSH) level of greater than 35 mIU/mL.
  • Males with female partners of childbearing potential must agree to use physician-approved contraceptive methods (e.g., abstinence, condoms, or vasectomy) for at least one month after completion of conditioning.

Exclusion Criteria:

• Diagnoses that do not require myeloablative transplant for cure (e.g. NK- SCID patients), unless the subject previously did not engraft with non-myeloablative or reduced intensity conditioning transplant.
• Known or suspected sensitivity to chemotherapy or radiation (e.g Fanconi's anemia, Dyskeratosis congenita, Ligase IV deficiency, etc).
• Subjects with fast-progressing neurodegenerative disorders (e.g. Krabbe disease or adrenal leukodystrophy with Loes score of ≥10)
• Cytopenias with increased blasts (>5%)
• Presence of anti-donor HLA antibodies (positive anti-donor HLA antibody is defined as a positive cross-match test of any titer (by complement-dependent cytotoxicity or flow cytometric testing) or the presence of anti-donor HLA antibody to the high expression loci HLA-A, B, C, DRB1 with mean fluorescence intensity (MFI)>3000 by solid phase
• Prior allogeneic stem cell transplant, except for patients with immune deficiencies who underwent previous non-myeloablative or reduced intensity transplants.
• Haploidentical donor using in vivo T-cell depletion (e.g. post-transplant cyclophosphamide).
• Uncontrolled bacterial, viral, or fungal infection at the time of enrollment. Uncontrolled is defined as currently taking medication and with progression or no clinical improvement on adequate medical treatment.
• Seropositive for HIV
• Active Hepatitis B or C determined by a detectable viral load of HBV or HCV by PCR
• Bridging fibrosis or liver cirrhosis
• Females or males of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 1 months after the end of conditioning
• Females who are pregnant or breastfeeding
• History of any other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician.
• Subjects demonstrating an inability to understand the study and comply with the study and/or follow-up procedures

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Sequential Assignment
• Masking: None (Open Label)

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group A--Thiotepa single dose; Fully matched 10/10 subjects with lower risk of graft failure. Subjects will undergo 10/10 HLA (human leukocyte antigen) matched bone marrow and peripheral blood transplant. Subjects receive combination of single daily dose thiotepa (5 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).	Drug: Thiotepa--single daily dose; Conditioning regimen for hematopoietic stem-cell transplant. Single daily IV dose of Thiotepa at 5 mg/kg.
Experimental: Group A--Thiotepa escalated dose; Fully matched 10/10 subjects with lower risk of graft failure. Subjects will undergo 10/10 HLA (human leukocyte antigen) matched bone marrow and peripheral blood transplant. Subjects receive combination of escalated dose of thiotepa (10 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).	Drug: Thiotepa--escalated dose; Twice daily IV dose of Thiotepa at 5 mg/kg, twelve hours apart, 10mg/kg total.
Active Comparator: Group B--Thiotepa single dose; Subjects with higher risk of graft failure. Subjects will undergo transplant with <10/10 bone marrow or peripheral blood match, or receiving cord blood transplant. Subjects receive combination of single daily dose thiotepa (5 mg/kg) added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).	Drug: Thiotepa--single daily dose; Conditioning regimen for hematopoietic stem-cell transplant. Single daily IV dose of Thiotepa at 5 mg/kg.
Active Comparator: Group B--Thiotepa escalated dose; Subjects with higher risk of graft failure. Subjects will undergo transplant with <10/10 bone marrow or peripheral blood match, or receiving cord blood transplant. Subjects receive combination of escalated dose of thiotepa (10 mg/kg)added to the backbone of targeted reduced dose IV busulfan, fludarabine and rabbit anti-thymocyte globulin (rATG).	Drug: Thiotepa--escalated dose; Twice daily IV dose of Thiotepa at 5 mg/kg, twelve hours apart, 10mg/kg total.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assessment of Minimum Effective Dose (MED) of Thiotepa	Assess the MED of thiotepa in combination with reduced-dose busulfan, fludarabine and rATG required to achieve engraftment in >90% subjects undergoing hematopoietic stem cell transplantation for non-malignant disorders.	Day 42

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percentage of Subjects With Graft Rejection/Failure.	Percentage of all subjects who initiated conditioning regimen and have sustained engraftment failure.	Day 42; Day 365
Percentage of Subjects Without Disease Recurrence Who Are Alive at 24 Months Post Transplant	Percentage of subjects who initiated conditioning regimen and are without evidence of underlying disease (DFS).	Month 24
Percentage of Subjects Alive at 24 Months Post Transplant (OS)	Percentage of subjects who initiated conditioning regimen and are alive at 24 months post transplant (OS).	Month 24
Evaluation of Transplant-related Mortality	Percentage of subjects who initiated conditioning regimen and who died due to a cause unrelated to the underlying disease.	Month 12
Number of Participants With Grade 2-4 Acute Graft-versus-host Disease (GVDH)	Graft-versus host disease symptoms measured using Modified Glucksberg Staging Criteria. (Scale 0-4; with 4 being most severe)	Month 12
Percentage of Participants With Chronic Graft-versus-host Disease (cGVHD)	Measures the frequency of chronic graft-vs-host disease in Group A participants	Month 24
Percentage of Participants With Transplant-related Complications	Complications gathered via CIBMTR (Center for International Blood & Marrow Transplant Research) post-transplant form was tabulated and described by treatment received.	24 months

Collaborators and Investigators

• Sponsor: University of Florida
• Collaborators: Live Like Bella Pediatric Cancer Research
• Investigators: Principal Investigator: Biljana Horn, MD, University of Florida

Study record dates

Study Major Dates

• Study Start (Actual): June 15, 2018
• Primary Completion (Actual): February 17, 2022
• Study Completion (Actual): February 19, 2023

Study Registration Dates

• First Submitted: April 19, 2018
• First Submitted That Met QC Criteria: April 19, 2018
• First Posted (Actual): May 1, 2018

Study Record Updates

• Last Update Posted (Actual): September 15, 2023
• Last Update Submitted That Met QC Criteria: September 12, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Keywords: human leukocyte antigen (HLA)
• Additional Relevant MeSH Terms: Pathologic Processes; Metabolic Diseases; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Immune System Diseases; Lymphatic Diseases; Immunoproliferative Disorders; Demyelinating Diseases; Neurologic Manifestations; Neurobehavioral Manifestations; Endocrine System Diseases; Disease Attributes; Disease; Bone Marrow Diseases; Hematologic Diseases; Infant, Newborn, Diseases; Blood Coagulation Disorders, Inherited; Hemorrhagic Disorders; Genetic Diseases, Inborn; Genetic Diseases, X-Linked; Connective Tissue Diseases; Blood Coagulation Disorders; Carbohydrate Metabolism, Inborn Errors; Metabolism, Inborn Errors; Lysosomal Storage Diseases; Mucinoses; Mental Retardation, X-Linked; Intellectual Disability; Heredodegenerative Disorders, Nervous System; DNA Repair-Deficiency Disorders; Blood Platelet Disorders; Agranulocytosis; Leukopenia; Leukocyte Disorders; Brain Diseases, Metabolic; Brain Diseases, Metabolic, Inborn; Anemia, Hemolytic, Congenital; Anemia, Hemolytic; Hemoglobinopathies; Anemia, Hypoplastic, Congenital; Anemia, Aplastic; Congenital Bone Marrow Failure Syndromes; Leukoencephalopathies; Phagocyte Bactericidal Dysfunction; Histiocytosis, Non-Langerhans-Cell; Histiocytosis; Adrenal Gland Diseases; Primary Immunodeficiency Diseases; Lymphopenia; Hereditary Central Nervous System Demyelinating Diseases; Peroxisomal Disorders; Adrenal Insufficiency; Red-Cell Aplasia, Pure; Mucopolysaccharidoses; Chronic Disease; Syndrome; Mucopolysaccharidosis I; Neutropenia; Immunologic Deficiency Syndromes; Anemia; Anemia, Sickle Cell; Thrombocytopenia; Granulomatous Disease, Chronic; Thalassemia; Lymphoproliferative Disorders; Lymphohistiocytosis, Hemophagocytic; Severe Combined Immunodeficiency; Wiskott-Aldrich Syndrome; Bone Marrow Failure Disorders; Pancytopenia; Adrenoleukodystrophy; Anemia, Diamond-Blackfan; Common Variable Immunodeficiency; Mannosidase Deficiency Diseases; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Antineoplastic Agents, Alkylating; Alkylating Agents; Myeloablative Agonists; Thiotepa
• Other Study ID Numbers: IRB201800798; PEDS024 (Other Identifier: UF Health); OCR17838 (Other Identifier: Universiy of Florida); AWD05935 (Other Grant/Funding Number: Live Like Bella Pediatric Cancer Research)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: There is no plan at this time.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No